1 d - অনুবাদ করা

Oral Drug Povorcitinib Enters Phase III Trial For Vitiligo

The first patient has enrolled in a China Phase III clinical trial of the oral drug povorcitinib for vitiligo. The trial will test the JAK1 inhibitor in adults with non-segmental vitiligo which causes patches of skin to lose pigment. The study is multi-center randomized double-blind and placebo-controlled to measure safety and efficacy. Vitiligo affects the immune system and can cause visible white patches that affect confidence and quality of life. Povorcitinib works by calming overactive immune signals that attack pigment producing cells. Earlier trials suggested the drug could help repigmentation and researchers now want to confirm the benefit in a larger group. Results from the trial will guide whether the treatment can move toward wider use in China.

image
advertisement
"We will never ask you to login, or register through a third-party advertisement."